BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 2, 2005
View Archived Issues
Diabetes Drug Glumetza Gets Approvable Letter From FDA
The FDA issued an approvable letter for Glumetza, a once-daily, extended-release version of the diabetes drug metformin, driving up Depomed Inc.'s stock value by 11 percent. (BioWorld Today)
Read More
Tysabri Crisis Causes Analysts To Downgrade, Revise Models
Read More
Perlegen Building Pipeline Via $74M Financing Round
Read More
Follow-On Protein Meeting Sheds More Light On Topic
Read More
Discovery Acquires Biofrontera, Expects To Lose Money In 2005
Read More
Other News To Note
Read More